Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CREB1 | P16220 | 4/20 | 0.62 |
| ▸ | FLT3 | P36888 | 2/20 | 0.62 |
| ▸ | SLCO2B1 | O94956 | 1/20 | 0.62 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.62 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.62 |
| ▸ | PRSS3 | P35030 | 1/20 | 0.62 |
| ▸ | PTPRS | Q13332 | 1/20 | 0.60 |
| ▸ | ABCB1 | P08183 | 3/20 | 0.58 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.58 |
| ▸ | POLB | P06746 | 2/20 | 0.58 |
| ▸ | MAPT | P10636 | 2/20 | 0.58 |
| ▸ | ABCG2 | Q9UNQ0 | 2/20 | 0.58 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.58 |
| ▸ | RECQL | P46063 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL433000 | 0.96 | CREB1 (0.60) | CREB1FLT3SLCO2B1PRSS1PRSS2 | |
| SCHEMBL12792821 | 0.88 | ABCB1 (0.66) | CREB1ABCB1KDM4EPOLBABCG2 | |
| Mosloflavone SCHEMBL29477310 | 0.83 | KDM4E (0.81) | CREB1FLT3SLCO2B1PRSS1PRSS2 | |
| Mosloflavone SCHEMBL971985 | 0.83 | KDM4E (0.81) | CREB1FLT3SLCO2B1PRSS1PRSS2 | |
| SCHEMBL7608398 | 0.81 | CREB1 (0.68) | CREB1FLT3SLCO2B1PRSS1PRSS2 | |
| SCHEMBL29074013 | 0.79 | CREB1 (0.69) | CREB1FLT3SLCO2B1PRSS1PRSS2 | |
| SCHEMBL973627 | 0.79 | CREB1 (0.74) | CREB1FLT3SLCO2B1PRSS1PRSS2 | |
| SCHEMBL30577296 | 0.79 | CREB1 (0.69) | CREB1FLT3SLCO2B1PRSS1PRSS2 | |
| SCHEMBL12847524 | 0.79 | FLT3 (0.63) | CREB1FLT3SLCO2B1PRSS1PRSS2 | |
| SCHEMBL21335353 | 0.79 | CREB1 (0.74) | CREB1FLT3SLCO2B1PRSS1PRSS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7855200-B2 | Method for treatment of gastric ulcers and ulcers induced by aspirin | COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH (IN) | 2010-12-21 | — | — | US | disclosed |
| US-20070213281-A1 | Natural agent for treatment of gastrointestinal toxicity, associated symptoms and ulcers | COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH (IN) | 2007-09-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070213281-A1 | Natural agent for treatment of gastrointestinal toxicity, associated symptoms and ulcers | FABP6, MLN, SI | CREB1 2738/4885FLT3 4324/4885SLCO2B1 2596/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.